SLAMF7 and plasma cell myeloma: In support of this hypothesis, high CD319 expression has been observed on plasma cells or B cells from several disease indications including systemic lupus erythematosus [17], and the transformed cells in multiple myeloma [16] indicating the potential for CD319 as a therapeutic target for plasmablast and/or plasma cell-driven diseases.